JOP20240106A1 - تقليل الكورتيكوستيرويد في العلاج بالأجسام المضادة ل cd38 - Google Patents
تقليل الكورتيكوستيرويد في العلاج بالأجسام المضادة ل cd38Info
- Publication number
- JOP20240106A1 JOP20240106A1 JOJO/P/2024/0106A JOP20240106A JOP20240106A1 JO P20240106 A1 JOP20240106 A1 JO P20240106A1 JO P20240106 A JOP20240106 A JO P20240106A JO P20240106 A1 JOP20240106 A1 JO P20240106A1
- Authority
- JO
- Jordan
- Prior art keywords
- reducing
- corticosteroids
- antibody therapy
- corticosteroid
- hematological malignancies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163275157P | 2021-11-03 | 2021-11-03 | |
| US202163280791P | 2021-11-18 | 2021-11-18 | |
| US202163288785P | 2021-12-13 | 2021-12-13 | |
| US202263394726P | 2022-08-03 | 2022-08-03 | |
| PCT/IB2022/060616 WO2023079494A1 (en) | 2021-11-03 | 2022-11-03 | Corticosteriod reduction in treatment with anti-cd38 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20240106A1 true JOP20240106A1 (ar) | 2024-05-01 |
Family
ID=84361138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOJO/P/2024/0106A JOP20240106A1 (ar) | 2021-11-03 | 2024-05-01 | تقليل الكورتيكوستيرويد في العلاج بالأجسام المضادة ل cd38 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230136301A1 (https=) |
| EP (1) | EP4426435A1 (https=) |
| JP (1) | JP2024540304A (https=) |
| KR (1) | KR20240099411A (https=) |
| AU (1) | AU2022380155A1 (https=) |
| CA (1) | CA3237175A1 (https=) |
| CL (1) | CL2024001324A1 (https=) |
| IL (1) | IL312514A (https=) |
| JO (1) | JOP20240106A1 (https=) |
| MX (1) | MX2024005406A (https=) |
| WO (1) | WO2023079494A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025080911A1 (en) * | 2023-10-12 | 2025-04-17 | Janssen Biotech, Inc. | Methods for treating multiple myeloma comprising an anti-cd38 antibody combined with bortezomib, lenalidomide and dexamethasone |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| ES2532399T3 (es) | 2003-03-05 | 2015-03-26 | Halozyme, Inc. | Glicoproteína hialuronidasa soluble (sHASEGP), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden |
| DK2511297T3 (en) | 2004-02-06 | 2015-06-15 | Morphosys Ag | Human anti-CD38 antibodies and their applications |
| EP2567976B1 (en) | 2005-03-23 | 2017-07-19 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| TW200745162A (en) | 2005-05-24 | 2007-12-16 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
| EP2860192B1 (en) | 2005-10-12 | 2017-09-27 | MorphoSys AG | Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38 |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| JP2011507519A (ja) | 2007-12-19 | 2011-03-10 | セントコア・オーソ・バイオテツク・インコーポレーテツド | ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| EA033110B1 (ru) | 2012-04-11 | 2019-08-30 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы |
| ES2774976T3 (es) | 2013-04-29 | 2020-07-23 | Teva Pharmaceuticals Australia Pty Ltd | Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| MX2017001079A (es) | 2014-07-24 | 2017-09-12 | Bluebird Bio Inc | Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma). |
| SI3227339T1 (sl) | 2014-12-05 | 2022-02-28 | Memorial Sloan-Kettering Cancer Center | Himerni antigenski receptorji, ki ciljajo na receptor, povezan z G-proteinom, in njihova uporaba |
| EA036379B1 (ru) | 2014-12-12 | 2020-11-02 | Блубёрд Био, Инк. | Химерные антигенные рецепторы к bcma |
| MX389805B (es) * | 2015-05-20 | 2025-03-11 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38. |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| US10072088B2 (en) | 2015-08-17 | 2018-09-11 | Janssen Pharmaceutica, Nv | Anti-BCMA antibodies and uses thereof |
| DE102016211884A1 (de) | 2016-06-30 | 2018-01-04 | Zf Friedrichshafen Ag | Getriebe für ein Kraftfahrzeug, sowie Antriebsstrang für ein Kraftfahrzeug |
| TWI781108B (zh) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| EP4282877A3 (en) | 2016-08-10 | 2024-02-21 | Legend Biotech Ireland Limited | Chimeric antigen receptors targeting bcma and methods of use thereof |
| MA53122A (fr) | 2018-07-13 | 2021-05-19 | Genmab As | Variants d'anticorps cd38 et leurs utilisations |
| WO2020081881A2 (en) * | 2018-10-17 | 2020-04-23 | Janssen Biotech, Inc. | Method of providing subcutaneous administration of anti-cd38 antibodies |
| JP7303314B2 (ja) | 2019-01-18 | 2023-07-04 | ヤンセン バイオテツク，インコーポレーテツド | Ｇｐｒｃ５ｄキメラ抗原受容体及びそれを発現する細胞 |
| US20200308297A1 (en) * | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses |
-
2022
- 2022-11-03 US US17/979,874 patent/US20230136301A1/en not_active Abandoned
- 2022-11-03 AU AU2022380155A patent/AU2022380155A1/en active Pending
- 2022-11-03 CA CA3237175A patent/CA3237175A1/en active Pending
- 2022-11-03 US US17/980,149 patent/US20230134748A1/en active Pending
- 2022-11-03 MX MX2024005406A patent/MX2024005406A/es unknown
- 2022-11-03 KR KR1020247018523A patent/KR20240099411A/ko active Pending
- 2022-11-03 EP EP22809519.6A patent/EP4426435A1/en active Pending
- 2022-11-03 IL IL312514A patent/IL312514A/en unknown
- 2022-11-03 JP JP2024526616A patent/JP2024540304A/ja active Pending
- 2022-11-03 WO PCT/IB2022/060616 patent/WO2023079494A1/en not_active Ceased
-
2024
- 2024-04-30 CL CL2024001324A patent/CL2024001324A1/es unknown
- 2024-05-01 JO JOJO/P/2024/0106A patent/JOP20240106A1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3237175A1 (en) | 2023-05-11 |
| JP2024540304A (ja) | 2024-10-31 |
| AU2022380155A1 (en) | 2024-06-20 |
| US20230134748A1 (en) | 2023-05-04 |
| KR20240099411A (ko) | 2024-06-28 |
| IL312514A (en) | 2024-07-01 |
| MX2024005406A (es) | 2024-08-06 |
| EP4426435A1 (en) | 2024-09-11 |
| WO2023079494A1 (en) | 2023-05-11 |
| US20230136301A1 (en) | 2023-05-04 |
| CL2024001324A1 (es) | 2024-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024012131A (es) | Composicion farmaceutica, uso de la misma y metodo para tratar el cancer | |
| JOP20200156A1 (ar) | إيسكيتامين لعلاج الاكتئاب | |
| MX2020009842A (es) | Uso de conjugados de anticuerpo-farmaco que comprenden agentes interruptores de tubulina para tratar tumor solido. | |
| MX2018011054A (es) | Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3. | |
| MX385543B (es) | Uso de un anticuerpo biespecífico para tratar cáncer de linfocitos b. | |
| AR105027A1 (es) | Métodos de tratamiento del cáncer de mama localmente avanzado o metastásico usando antagonistas del eje de pd-1 y taxanos | |
| PH12018500174A1 (en) | Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer | |
| MX2023013227A (es) | Regimen de dosis para terapia combinada dirigida a dll3 y pd-1. | |
| MX2022007761A (es) | Usos de anticuerpos anti-tgf? e inhibidores de punto de control para el tratamiento de enfermedades proliferativas. | |
| EA201992430A1 (ru) | Комбинированная терапия рака предстательной железы | |
| RU2018103064A (ru) | Комбинация ингибитора hdac и анти-pd-l1-антитела для лечения злокачественной опухоли | |
| MX2024004213A (es) | Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados. | |
| JOP20240106A1 (ar) | تقليل الكورتيكوستيرويد في العلاج بالأجسام المضادة ل cd38 | |
| ZA202304965B (en) | Combination therapy for treating cancer | |
| MX2021007391A (es) | Regimenes de baja dosis extendida para inhibidores de mdm2. | |
| Bokobza et al. | Short-course treatment with gefitinib enhances curative potential of radiation therapy in a mouse model of human non-small cell lung cancer | |
| MX2021010402A (es) | Tratamiento de la hidradenitis supurativa. | |
| JP2018522028A5 (https=) | ||
| JP2017537927A5 (https=) | ||
| BR112022010806A2 (pt) | Métodos para tratar câncer de mama, para inibir o crescimento tumoral e para prevenir ou retardar o desenvolvimento de resistência de um câncer de mama | |
| ZA201907754B (en) | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer | |
| JOP20240188A1 (ar) | معالجة سرطان تستهدف dll3 | |
| MX2024007649A (es) | Paradigma de tratamiento para una terapia con anticuerpos anti cumulo de diferenciacion (anti-cd19). | |
| MX2023001233A (es) | Metodos de tratamiento del cancer positivo para her2 con tucatinib en combinacion con trastuzumab, un taxano y un antagonista del vegfr-2. | |
| CR20230014A (es) | Molécula de unión al antígeno anti-células t para usarse en combinación con un inhibidor de angiogénesis |